April 14, 2021
Business News

Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer


MINNEAPOLIS–()–Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced it has entered into a global licensing agreement with Pfizer Inc. (NYSE:PFE) granting Celcuity exclusive rights to Pfizer’s gedatolisib, a Phase 1b pan-PI3K/mTOR inhibitor. Gedatolisib is in clinical development for the treatment of patients with ER+/HER2-negative advanced or metastatic breast cancer.

Under the terms of the licensing agreement, Pfizer provided Celcuity with a worldwide license to develop and commercialize gedatolisib. Celcuity paid an upfront license fee of $5 million of cash and $5 million…



Click here to view the original article.

Related Posts

You might also like ...

PORCH GROUP ALERT: Bragar Eagel & Squire, P.C. Is Investigating Porch Group, Inc. on Behalf of Porch Group Stockholders and Encourages Investors to Contact the Firm
California Insurer Announces 15th Consecutive Dividend for Policyholders
CANAAN ALERT: Bragar Eagel & Squire, P.C. is Investigating Canaan, Inc. on Behalf of Canaan Stockholders and Encourages Investors to Contact the Firm